Media Articles | ICON plc

ICON experts frequently author or contribute to industry trade press.

Filter media

Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.

13 March 2023

LEO Pharma and ICON partner for clinical trial execution in dermatology

This news article, published on Clinical Trials Arena, outlines how the collaboration is expected to provide access to innovative clinical trials as well as help to launch new medicines.
10 March 2023

LEO Pharma and ICON enter strategic partnership

This news article, first published on Applied Clinical Trials, outlines that LEO Pharma and ICON have announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective.
10 March 2023

ICON and LEO Pharma join forces on clinical trial mission

This news article, published on PharmaTimes online, indicates how the collaboration will concentrate on launching and running studies within medical dermatology.
10 March 2023

LEO Pharma, ICON partner to advance clinical trials in dermatology

This news article, first published on Contract Pharma, covers the strategic partnership between LEO Pharma and ICON to propel clinical trial execution within medical dermatology.
22 February 2023

The significant increase in demand for Clinical Research Associates (CRAs)

Helen Yeardley, Senior Vice President, Clinical Operations, offers her insights on the role that a Clinical Trial Associate (CRA) plays in the clinical trial process.
16 December 2022

Turning an ocean of data into actionable wisdom to support optimal site identification

Travis Caudill, VP Feasibility & Clinical Informatics, offers his insights on how advancements in AI can help the pharmaceutical industry identify the best sites for their clinical trials through the harnessing of Big Data.
Innovations in Pharmaceutical Technology, December 2022, pages 24-25. Samedan Ltd
08 December 2022

The evolving relationship between sponsors and contract research organisations

If the last few years have taught us anything, it’s that so much more can be achieved when all players in the life sciences and pharmaceutical industries work together in a truly collaborative way. The opportunity for the clinical development industry is to take what we have learned about how we can work together and use this to continue to drive progress. To strategically support clients, at ICON, this means partnering with sponsors in a way that goes beyond a traditional CRO. It means being a trusted partner.

In this podcast and article Jeff James, EVP Alliance Management, offers his perspective on what it takes to be a trusted partner to sponsors in the clinical development industry.
06 December 2022

Drug development practices to improve public health policy

In this article, Dr Andrew Garrett, Executive Vice President of Scientific Operations, explores the need for interdisciplinary collaboration between pharmaceutical and non-pharmaceutical researchers and public health centres to consider the overlap between NPIs and PIs and identify where standards can be improved and enforced.
04 November 2022

Expert Q&A: The impact of the clinical trial liaison function
Expert Q&A: The impact of the clinical trial liaison function
The clinical trial liaison (CTL) function was first introduced in 2014 to help sponsors differentiate themselves from the competition by driving recruitment success in clinical trials.
FirstWord spoke with Elizabeth Pash, Senior Director of Global Site Engagement Operations at ICON, to find out exactly what this relatively new role involves, its value in developing and delivering optimal clinical trials and how it is set to evolve in future.
Summary points from the interview:
- In the competitive world of pharmaceutical research, sponsors can differentiate themselves by driving recruitment success in clinical trials.
- The CTL role was introduced in 2014 to bring doctorate-trained clinical research professionals into the clinical trial process to support site identification, activation and recruitment, ensuring optimal productivity of clinical trials.
- While CTLs and clinical research associates (CRAs) are both considered protocol experts and build relationships with sites, CTLs focus on the scientific aspects of a protocol rather than the eligibility criteria and schedule of assessments.
- At ICON, CTLs have contributed to a 20% boost in the targeted recruitment rate and helped approximately 70% of sites achieve their baseline recruitment goals. In the past five years, they have also helped sponsors bring nine new compounds to market and receive two new indication approvals for already-approved medications.
- As more clinical trials begin to incorporate more decentralised approaches, the need for roles like CTLs is set to steadily increase across the industry.
- Potential is increasing for CTLs to establish partnerships earlier with sponsors, supporting trial and protocol design, conducting targeted investigator interviews and applying the information in the early stages of clinical development.
[Subscription is required to view the entire interview]
20 September 2022

Redefining CRO sourcing model terminology to optimise outsourcing strategies

Samir Shah, President, Strategic Solutions at ICON contributes to this Applied Clinical Trials article discussing the compelling need for new terminology for sourcing models in the CRO industry.
Reprinted with permission from Applied Clinical Trials. Applied Clinical Trials is a copyrighted publication of MultiMedia Healthcare, LLC. All rights reserved.